Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christa Haugaard Nyhus

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Ugeskrift for Laeger|November 25, 2022
Uffe Mark Lauridsen, Joyce Dominique J Horsmans Schultz, Christa Haugaard Nyhus, et al.
Translational Lung Cancer Research|March 15, 2021
The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancerSara Witting Christensen Wen, Rikke Fredslund Andersen, Torben Frøstrup Hansen, et al.
Scientific Reports|April 18, 2024
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapySinne Søberg Brun, Torben Frøstrup Hansen, Sara Witting Christensen Wen, et al.
British Journal of Cancer|May 3, 2023
NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitorsSara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, et al.
Acta Oncologica (Stockholm, Sweden)|November 7, 2023
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecanMorten Mau-Sørensen, Jonas Gerner-Rasmussen, Olfred Hansen, et al.
BMJ Open|February 2, 2026
ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocolMichael Elmkvist Andersen, Christa Haugaard Nyhus, Weronika Maria Szejniuk, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 17, 2026
The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancerThomas Leth Fink, Rikke Fredslund Andersen, Cecilie Mondrup Jacobsen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 10, 2017
Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III studyDitte Sloth Møller, Tine Bjørn Nielsen, Carsten Brink, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Ugeskrift for Laeger|November 25, 2022
Uffe Mark Lauridsen, Joyce Dominique J Horsmans Schultz, Christa Haugaard Nyhus, et al.
Translational Lung Cancer Research|March 15, 2021
The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancerSara Witting Christensen Wen, Rikke Fredslund Andersen, Torben Frøstrup Hansen, et al.
Scientific Reports|April 18, 2024
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapySinne Søberg Brun, Torben Frøstrup Hansen, Sara Witting Christensen Wen, et al.
British Journal of Cancer|May 3, 2023
NK cell activity and methylated HOXA9 ctDNA as prognostic biomarkers in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitorsSara Witting Christensen Wen, Line Nederby, Rikke Fredslund Andersen, et al.
Acta Oncologica (Stockholm, Sweden)|November 7, 2023
Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecanMorten Mau-Sørensen, Jonas Gerner-Rasmussen, Olfred Hansen, et al.
BMJ Open|February 2, 2026
ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA-PRediction in LUng CAncer Treatment) - study protocolMichael Elmkvist Andersen, Christa Haugaard Nyhus, Weronika Maria Szejniuk, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 17, 2026
The prognostic value of methylated ctDNA, soluble PD-L1, and NK-cell activity on the risk of relapse after curative radiotherapy of non-small cell lung cancerThomas Leth Fink, Rikke Fredslund Andersen, Cecilie Mondrup Jacobsen, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 10, 2017
Heterogeneous FDG-guided dose-escalation for locally advanced NSCLC (the NARLAL2 trial): Design and early dosimetric results of a randomized, multi-centre phase-III studyDitte Sloth Møller, Tine Bjørn Nielsen, Carsten Brink, et al.
Pageof 1